China Producător de pulbere de steroizi anabolizanți
EnglishAfrikaansБългарскиNederlandsFrançaisDeutschItaliano日本語LatīnaNorskپارسیPolskiPortuguêsRomânăРусскийSlovenčinaSlovenščinaEspañolSvenskaTürkçeУкраїнськаудмурт кыл

Peptide farmaceutice

» Peptide » Peptide farmaceutice

  • Specificații
  • Descriere produs
  • Utilizarea produsului

numele produsului:Lixisenatidă

CAS:320367-13-3

MF:C215H347N61O65S

MW:4858.53

Lixisenatidă (trade name Lyxumia in the European Union and Adlyxin in the U.S. and manufactured by Sanofi) is a once-daily injectable GLP-1 receptor agonist for the treatment of type 2 Diabet.

Lixisenatidă (Lyxumia, Adlyxin, Peptida ZP10A, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.

Lixisenatide is used as adjunct to diet and exercise to treat type 2 diabetes.In the European Union, its use is limited to complementing insulin therapy.As of 2017 it is unclear if they affect a person's risk of death.

It is provided in an autoinjector containing fourteen doses and is injected subcutaneously.

Lixisenatide should not be used for people who have problems with stomach emptying.Lixisenatide delays emptying of the stomach, which may change how quickly other drugs that are taken by mouth take effect.

Formular de solicitare ( vă vom reveni cât mai curând posibil )

Nume:
*
E-mail:
*
Mesaj:

Verificare:
2 + 5 = ?

Poate iti place si tie

  • Avantajul nostru

    Preț bun

    Calitate superioară

    Livrare rapidă

    Expediere sigură

    Servicii post-vânzare excelente

  • Depozitul local

    Depozitul UE

    Depozitul din Marea Britanie

    Depozitul SUA

    Depozitul Canada

    Depozitul Australia

  • Modalitate de plată

    Paypal

    Bitcoin

    Transfer bancar

    Money Gram

    Western Union

  • Contactaţi-ne

    E-mail: jacob@steroid-peptide.com

    WhatsApp: +8615636286252

    Telefon: 0086-15636286252

    Site-ul web: www.steroid-peptide.com

    Bun venit întrebarea dvs